Real-life study of benralizumab in adults with eosinophilic granulomatosis with polyangiitis
Follows adults with EGPA treated with benralizumab, checking how well and how safely it works.
Plain-language title generated from the registry record
Registry title: Benralizumab Effectiveness in EGPA
Key facts
- Where
- Florence, ItalySee the site
Where in Italy
- Edoardo BiancalanaFlorence, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European EGPA Study Group
- Trial code
- NCT07815886
- Record updated
- 11 September 2026
- Original description
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. The study will include patients treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Clinical, laboratory, lung function, treatment, relapse, and safety data will be collected from medical charts at baseline and during follow-up up to 24 months.Read full original descriptionShow less
Benralizumab Effectiveness in the LONG-term Real-life Setting in EGPA: The BELONG-EGPA Study
This is a multicenter, retro-prospective observational study evaluating the effectiveness and safety of benralizumab in adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in a real-world setting. The study will include patients treated with benralizumab 30 mg every 4 weeks at EGPA referral centers participating in the European EGPA Study Group. Clinical, laboratory, lung function, treatment, relapse, and safety data will be collected from medical charts at baseline and during follow-up up to 24 months.
Inclusion: Age 18 years or older; Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) according to the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria or the criteria proposed in the MIRRA trial; Treatment with benralizumab 30 mg every 4 weeks; At least 3 months of available follow-up data after starting benralizumab; Written informed consent for study participation and data collection.
Exclusion: Age younger than 18 years; No available follow-up data after starting benralizumab; Follow-up after benralizumab initiation shorter than 3 months; Lack of written informed consent, where required by local regulations.